"ATTACK": Next-Generation T-Cell Immunotherapy Directed Against Lymphoid Malignancies

Project Details

Description

Adoptive T cell immunotherapy offers great potential for treating a variety of lymphoid malignancies. In particular, it has been shown that T cells specifically engineered to express of chimeric antigen receptors (CARs) can be efficiently re-directed against antigens expressed on lymphoid tumor cells. This has led to robust clinical responses in patients refractory to conventional therapies. Despite this progress, this state of the art immunotherapy is no 'magic bullet' and still suffers from a number of limitations. More specifically, immune escape variants
can emerge that are resistant to the engineered T cells. Moreover, infusion of engineered allogeneic T cells can provoke potentially life-threatening side-effects such as graft versus host disease (GvH) or cytokine release syndrome. This project focuses on the development of nextgeneration immunotherapy for lymphoid malignancy using a multi-pronged gene therapy
approach to overcome these limitations, while maintaining the therapeutic advantage of using tumor-specific T cells to combat cancer.
AcronymFWOTM786
StatusFinished
Effective start/end date1/10/1530/09/19

Flemish discipline codes

  • Cancer therapy

Keywords

  • cancer